Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262

Watchlist Manager
Jiangsu Nhwa Pharmaceutical Co Ltd Logo
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
Watchlist
Price: 24.51 CNY 0.04% Market Closed
Market Cap: 24.9B CNY

Jiangsu Nhwa Pharmaceutical Co Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jiangsu Nhwa Pharmaceutical Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
Pre-Tax Income
ÂĄ1.4B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
16%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ5.7B
CAGR 3-Years
20%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ2.8B
CAGR 3-Years
-1%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ8.5B
CAGR 3-Years
40%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ6.3B
CAGR 3-Years
28%
CAGR 5-Years
2%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Pre-Tax Income
ÂĄ4B
CAGR 3-Years
N/A
CAGR 5-Years
218%
CAGR 10-Years
N/A
No Stocks Found

Jiangsu Nhwa Pharmaceutical Co Ltd
Glance View

Market Cap
24.7B CNY
Industry
Pharmaceuticals

Jiangsu Nhwa Pharmaceutical Co., Ltd. is an intriguing player in the pharmaceutical industry, operating with a robust focus on innovative therapeutic solutions. Headquartered in the bustling economic landscape of China, the company has carved a niche for itself primarily in the central nervous system (CNS) sector. Nhwa Pharmaceutical leverages advanced research and development to craft medications aimed at treating a variety of CNS disorders, including depression, schizophrenia, and epilepsy. This specialization in a highly complex and demanding field underscores the company's commitment to addressing some of the most challenging health issues faced by modern society. By advancing its expertise in this area, Nhwa ensures a steady stream of cutting-edge products that form the backbone of its revenue. The company's financial model strongly revolves around the development and commercialization of high-demand medications. Nhwa's revenues are primarily derived from domestic and international sales of its pharmaceuticals. It also invests considerably in maintaining a pipeline of products that are either in the development or regulatory approval stages. This strategic focus on a balanced product portfolio enables Nhwa to remain resilient against market fluctuations. Their investments in research are complemented by collaborations with academic institutions and other pharmaceutical enterprises, further amplifying their reach and competitiveness. This formula allows Nhwa Pharmaceutical to not only capture significant market share but also contribute meaningfully to the ongoing evolution of medical treatments in its chosen specialties.

Intrinsic Value
29.61 CNY
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Jiangsu Nhwa Pharmaceutical Co Ltd's Pre-Tax Income?
Pre-Tax Income
1.4B CNY

Based on the financial report for Sep 30, 2025, Jiangsu Nhwa Pharmaceutical Co Ltd's Pre-Tax Income amounts to 1.4B CNY.

What is Jiangsu Nhwa Pharmaceutical Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
16%

Over the last year, the Pre-Tax Income growth was 4%. The average annual Pre-Tax Income growth rates for Jiangsu Nhwa Pharmaceutical Co Ltd have been 12% over the past three years , 11% over the past five years , and 16% over the past ten years .

Back to Top